✨ Onyx Summary Lexicon Pharmaceuticals will present clinical data for its investigational AAK1 inhibitor, pilavapadin, at three meetings: NeuroDiab (Sept. 13, 2025, Bucharest), EASD (Sept. 17, 2025, Vienna), and Arrowhead’s Pain Therapeutics Summit (Oct. 13–14, 2025, San Diego), with sessions led by Dr. Rodica Pop-Busui and Dr. Suma Gopinathan.
✨ Onyx Summary Avidity Biosciences priced an upsized public offering of 15 million shares at $40 each, expected to raise $600 million before expenses, with underwriters granted a 30-day option to purchase up to 2.25 million additional shares. Proceeds will be used to advance its three late-stage RNA therapeutic programs,
"I never set out to be a CEO - I was just the guy saying yes to everything,” Patrick Verkland reveals how hands-on startup lessons prepared him to scale a sustainable oral care brand worldwide.
✨ Onyx Summary Guardant Health announced a strategic agreement with LabFlorida/SunDx Labs to make its FDA-approved Shield™ blood test for colorectal cancer screening available to residents of senior living communities across Florida. By extending Shield to this high-risk, underserved population, the partnership could transform preventive care in aging communities—removing
✨ Onyx Summary Avidity Biosciences reported new one-year data from the EXPLORE44 program showing that its exon 44–skipping therapy del-zota not only slowed but reversed disease progression in Duchenne muscular dystrophy patients, with improvements across multiple functional measures compared to natural history. Treatment led to sustained dystrophin production, normalization of
✨ Onyx Summary Avidity Biosciences (Nasdaq: RNA) announced plans to raise approximately $500 million through an underwritten public offering of its common stock, with an additional $75 million available to underwriters via a 30-day option. The company intends to use the proceeds to advance its three late-stage clinical programs, prepare for
"These projects are more than acts of goodwill," China's Health Silk Road is as much about soft power as it is about medicine.
"The holy grail is charging a heavy-duty truck in under 30 minutes. That’s what the whole industry is chasing,” Neha Palmer reveals why megawatt charging and smart siting are key to the EV freight transition.
“Pain is treated like a badge of honor" in medicine, but the cost is a workforce breaking under invisible pressure.
"AI has already been shown to be just as, if not more, accurate than dermatologists," Dr. Alexander Green explains, as DERM proves 99.8% effective at ruling out cancer.
✨ Onyx Summary Guardant Health has announced a partnership with PathGroup to expand access to its FDA-approved Shield™ blood test for colorectal cancer (CRC) screening. The collaboration will bring Shield to more than 250 hospitals and health systems, 15,000+ affiliated physicians, and millions of patients across 25 states through PathGroup’
✨ Onyx Summary Lexicon Pharmaceuticals submitted new clinical data to the FDA from three investigator-initiated studies supporting a potential resubmission of its New Drug Application for Zynquista® (sotagliflozin) as an adjunct to insulin therapy for adults with type 1 diabetes. The submission follows a 2024 FDA complete response letter citing safety
✨ Onyx Summary Keros Therapeutics presented additional Phase 1 data for KER-065 showing strong bone anabolic activity and increased bone mineral density in healthy volunteers, with the treatment well-tolerated across all dose levels. The results reinforce KER-065’s dual potential in Duchenne muscular dystrophy and bone disorders, supporting its continued clinical
✨ Onyx Summary Belite Bio entered an upsized PIPE financing led by RA Capital with participation from Eventide, Marshall Wace, RTW, Soleus, and Vestal Point, raising ~$125M upfront and issuing two-year warrants exercisable at a 20% premium ($76.80) for up to an additional ~$150M. The company will sell 1,953,
✨ Onyx Summary ImmunityBio reported Phase 2 data showing that ANKTIVA® (nogapendekin alfa inbakicept) can reverse therapy-induced lymphopenia in patients with checkpoint inhibitor–resistant advanced non-small cell lung cancer, with reversal linked to longer median overall survival (15.8 vs. 11.5 months; p=0.0057). The study suggests that restoring
"By simply replacing the plastic wrap, we eliminated the equivalent of 3.75 million plastic straws — or more than 190,000 plastic bottles,” Luiz Beling reveals how Apeel’s plant-based science is reshaping produce preservation.
